Pegvisomant
Pegvisomant (Somavert) je antagonist receptora hormona rasta koji se koristi u tretmanu akromegalije.[1][2][3]
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | ~6 dana |
| Identifikatori | |
| CAS broj | 218620-50-9  |
| ATC kod | H01AX01 (WHO) |
| DrugBank | DB00082 |
| ChEMBL | CHEMBL1201515 |
| Hemijski podaci | |
| Formula | C990H1532N262O300S7 |
| Molarna masa | 22129,0 g/mol |
| Fizički podaci | |
| Tačka topljenja | 76 °C (169 °F) |
Reference
уреди- ^ Schreiber, I; Buchfelder M; et al. (januar 2007). „Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study”. European Journal of Endocrinology. 156 (1): 75—82. PMID 17218728. doi:10.1530/eje.1.02312. Архивирано из оригинала 14. 04. 2013. г. Приступљено 16. 12. 2013.
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
уреди- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
уреди | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
